You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ceritinib

Showing 1 - 25 of 61
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ALK-positive NSCLC Trial in Dallas (Ceritinib, Stereotactic ablative body radiation)

Terminated
Has Results
  • ALK-positive Non-small Cell Lung Cancer
  • Ceritinib
  • Stereotactic ablative body radiation
  • Dallas, Texas
    UT Southwestern Medical Center
Jan 31, 2023

NSCLC Trial in Davis, San Francisco (Ceritinib, Trametinib)

Terminated
  • Non-small Cell Lung Cancer
  • Davis, California
  • +1 more
Dec 22, 2022

Cancer Trial in Jinan (Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs))

Recruiting
  • Cancer
  • Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs)
  • Jinan, Shandong, China
    Shandong Provincial Qianfoshan Hospital
Jul 18, 2022

ALK Positive Tumors Trial (ceritinib)

No longer available
  • ALK Positive Tumors
  • ceritinib
  • (no location specified)
Nov 30, 2021

High-risk Neuroblastoma Trial in Charlotte (Naxitamab, Ceritinib)

Not yet recruiting
  • High-risk Neuroblastoma
  • Charlotte, North Carolina
    Levine Children's Hospital
Aug 4, 2022

Cancer Medicines in Metastatic Non-small Cell Lung Cancer in

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Oslo, Norway
    Pfizer Norway
Apr 17, 2023

Neuroblastoma, Cancer Trial in Philadelphia (procedure, genetic, other, behavioral, drug)

Terminated
  • Neuroblastoma
  • Cancer
  • Biopsy
  • +12 more
  • Philadelphia, Pennsylvania
    The Children's Hospital of Philadelphia
Jan 31, 2023

NSCLC Trial in Worldwide (ceritinib)

Completed
  • Non-Small Cell Lung Cancer
  • ceritinib
  • Fayetteville, Arkansas
  • +72 more
Feb 7, 2022

ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

Completed
Has Results
  • ALK-positive NSCLC
  • Sollentuna, Sweden
    Pfizer Innovations AB
Mar 14, 2022

free Survival and Evaluate Participant Experience for Metastatic

Active, not recruiting
  • Anaplastic Lymphoma Kinase-positive
  • Carcinoma Non-small-cell Lung
  • Maynard, Massachusetts
    EmpiraMed, Inc.
Feb 28, 2022

Glioblastoma, Brain Metastases Trial in Phoenix (ceritinib 750mg)

Completed
  • Glioblastoma
  • Brain Metastases
  • ceritinib 750mg
  • Phoenix, Arizona
    Barrow Brain and Spine
Dec 10, 2020

NSCLC Trial in Worldwide (Ribociclib, Ceritinib)

Completed
  • Non-small Cell Lung Cancer
  • Boston, Massachusetts
  • +7 more
Dec 16, 2020

ALK-positive Advanced Tumors Trial in Worldwide (ceritinib, warfarin, midazolam)

Completed
  • ALK-positive Advanced Tumors
  • ceritinib
  • +2 more
  • Detroit, Michigan
  • +10 more
Dec 16, 2020

Tumors With Aberrations in ALK or ROS1 Trial in United States (Ceritinib)

Terminated
Has Results
  • Tumors With Aberrations in ALK or ROS1
  • Ceritinib
  • Santa Rosa, California
  • +20 more
Mar 12, 2021

Soft Tissue Sarcoma Trial in France (drug, combination product, other)

Recruiting
  • Soft Tissue Sarcoma
  • Bordeaux, France
  • +17 more
Oct 4, 2022

ALK-positive Advanced NSCLC Trial in Worldwide (Brigatinib)

Active, not recruiting
Has Results
  • ALK-positive Advanced NSCLC
  • Orange, California
  • +79 more
Nov 15, 2022

Neuroblastoma Trial in United States (Ceritinib, dasatinib, sorafenib)

Recruiting
  • Neuroblastoma
  • Ceritinib
  • +4 more
  • Birmingham, Alabama
  • +23 more
Sep 26, 2022

ALK Fusion Protein Expression, BRAF wt Allele, Invasive Skin Melanoma Trial in San Francisco (Capmatinib, Ceritinib,

Terminated
Has Results
  • ALK Fusion Protein Expression
  • +14 more
  • San Francisco, California
    University of California, San Francisco
Jan 14, 2020

Tumors With Aberrations in ALK, Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumor Trial in Worldwide (Ceritinib

Terminated
Has Results
  • Tumors With Aberrations in ALK
  • +3 more
  • Ceritinib (LDK378)
  • Brno, Czech Republic, Czechia
  • +13 more
Dec 17, 2019

Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present, Systemic Anaplastic Large Cell Lymphoma

Withdrawn
  • Anaplastic Large Cell Lymphoma, ALK-Positive
  • +2 more
  • Brentuximab Vedotin
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 8, 2019

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse

Unknown status
  • Carcinoma, Non-Small-Cell Lung
  • Immune-Related Adverse Events
  • PD-1 inhibitor
  • Chemotherapy Drugs, Cancer
  • (no location specified)
May 27, 2020

Metastatic Anaplastic Thyroid Cancer, Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer Trial in Dallas (Ceritinib)

Withdrawn
  • Metastatic Anaplastic Thyroid Cancer
  • Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer
  • Ceritinib
  • Dallas, Texas
    UT Southwestern Medical Center
Jul 26, 2019

ALK-positive NSCLC Trial in Worldwide (Ceritinib)

Completed
Has Results
  • ALK-positive Non-small Cell Lung Cancer
  • Ceritinib
  • Los Angeles, California
  • +56 more
Apr 8, 2020

NSCLC Trial in Worldwide (Ceritinib, pemetrexed, docetaxel)

Active, not recruiting
Has Results
  • Non-Small Cell Lung Cancer
  • Ceritinib
  • +2 more
  • Fayetteville, Arkansas
  • +96 more
Dec 19, 2022

NSCLC Trial in Worldwide (Ceritinib, Pemetrexed, Cisplatin)

Active, not recruiting
Has Results
  • Non-Small Cell Lung Cancer
  • Ceritinib
  • +3 more
  • Woolloongabba, Queensland, Australia
  • +131 more
Oct 24, 2022